心脏瓣膜病介入治疗的变革与展望——技术创新驱动未来  

Revolution and outlook of interventional therapy for valvular heart disease:technological innovation driving the future

作　　者：王建安[1] WANG Jian'an(Department of Cardiology,Second Affiliated Hospital,Zhejiang University School of Medicine,State Key Laboratory of Transvascular Implantation Devices,Provincial Key Lab of Cardiovascular Research,Binjiang Institution of Zhejiang University,Hangzhou,310006,China)

机构地区：[1]浙江大学医学院附属第二医院心内科,经血管植入器械全国重点实验室,浙江省心血管病诊治重点实验室,浙江大学滨江研究院,杭州310006

出　　处：《临床心血管病杂志》2025年第3期165-169,共5页Journal of Clinical Cardiology

基　　金：浙江省“尖兵领雁+X”研发攻关计划(No:2024C03024);浙江大学滨江研究院项目(No:ZY202205SMKY001)。

摘　　要：心脏瓣膜病已成为全球范围内的重要健康问题,尤其在老龄化社会中,其发病率和病死率持续上升。在中国,随着人口老龄化的加剧,心脏瓣膜病的负担愈加沉重。传统的外科手术在治疗高龄或伴有多种合并症的患者时,存在较高风险。近年来,经导管介入治疗技术取得了显著进展,成为全球心脏瓣膜病治疗的重要选择。本文综述了近年来心脏瓣膜病介入治疗的最新进展,包括关键研究、技术创新、临床应用以及未来研究的方向。经导管主动脉瓣置换技术的不断拓展和经导管二、三尖瓣介入治疗的成功应用使得心脏瓣膜病的治疗手段更加多样化,且国产器械在全球临床试验中的应用也日益增多,展示了中国在这一领域的技术突破和市场潜力。未来,随着多组学与人工智能的结合、新型瓣膜器械的发展和无植入治疗的突破等,心脏瓣膜病的介入治疗将在精准性、安全性和耐久性方面取得进一步提升。Valvular heart disease(VHD)has become a significant global health issue,with its incidence and mortality continuously rising,particularly in aging society.In China,the burden of VHD has grown increasingly heavier due to the aging population.Traditional surgical interventions carry high risks when treating elderly patients or those with multiple comorbidities.In recent years,transcatheter interventions have made significant progress,becoming an important treatment option for VHD worldwide.This review summarizes the latest advancements in interventional therapy for VHD,including key studies,technological innovations,clinical applications,and future research directions.The ongoing promotion of transcatheter aortic valve replacement technology and the successful application of transcatheter mitral and tricuspid intervention treatments have diversified the available therapeutic options for VHD.Additionally,the growing use of domestic devices in global clinical trials highlights China's technological breakthroughs and market potential in this field.In the future,with the integration of multi-omics and artificial intelligence,the development of novel valve devices,and breakthroughs in non-implantable treatments,interventional therapies for VHD are expected to achieve further improvements in precision,safety,and durability.

关 键 词：心脏瓣膜病 经导管介入治疗 国产器械 技术创新 

分 类 号：R542.5[医药卫生—心血管疾病]